



Alaska Medical Assistance DUR Committee Meeting
Friday, November 15, 2019
Frontier Building, 3601 C Street; Room 890
1:00pm
1.800.315.6338, access code 24251#

Agenda

- (1) Review of minutes from September 2019
- (2) Review of Agenda
- (3) Comments/Suggestions from Committee members
- (4) Overview of Medicaid Prescription and Cost Trends
- (5) Prospective Drug Utilization Review / Clinical Topic Areas:
 - a. New Prescription Medications (Interim PA List – 6 month review)
 - i. Review of new medications to market since April meeting
 - b. New Prior Authorizations, Quantity Limits, Edits
 - i. Firadapse® and Ruzurgi®
 - ii. Vyndaqel® and Vyndamax™
 - iii. Corlanor®
 - iv. Xiaflex®
 - c. Review of existing Prior Authorizations, Quantity Limits, Edits
 - i. Oxycodone IR
 - ii. Hydromorphone
- (6) Opioid Use Trends and ICD-10 Report
- (7) Intervention Updates and Criteria
 - a. Liquid Oxycodone use in children
 - b. Stimulant age limits
- (8) FDA/DEA Updates
 - a. FDA Drug Safety Communications
- (9) FAERS Reports
- (10) Misc. DUR items
- (11) End of Public Meeting
- (12) Profile Review

Pharmaceutical Manufacturers wishing to submit unsolicited clinical information may do so via the form found at the link below:

http://dhss.alaska.gov/dhcs/Documents/pdf/Documents/AK_Submission_Request_Form_Pharm_Manufacturers.pdf

Submissions for the September meeting must be received no later than 4pm Alaska local time on Monday, October 30, 2019.